FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890908880> ?p ?o ?g. }

• W2890908880 endingPage "e18152" @default.
• W2890908880 startingPage "e18152" @default.
• W2890908880 abstract "e18152 Background: Data on the management of chronic hepatitis C virus (HCV) infection in cancer patients (pts) are sparse with many of them excluded from cancer clinical trials (CCT). We evaluated the efficacy and safety of sofosbuvir-based therapy (SOFBT) in such pts. Methods: Consecutiveptstreated with SOFBT at MD Anderson (1/2014-2/2017) were included in a prospective observational study. Efficacy (sustained virological response 12 weeks [SVR12] after SOFBT) was assessed based on intention to treat (ITT) analysis. A posthoc per-protocol analysis (PPA) was performed on pts with 12 weeks of follow-up post SOFBT. Adverse events (AEs) and drug-drug interactions (DDIs) were evaluated. Results: Of the 143 pts studied, the majority were men (102; 89%), white (89; 62%) and had genotype 1 (103; 72%). The most common cancers were non-Hodgkin lymphoma (NHL), hepatocellular carcinoma (HCC) (24; 17%, each) and breast cancer (11; 8%). Of the 31 infected pts excluded from CCTs, 27 (87%) were granted access after SVR. The overall SVR12 were 90% ITT (129/143) and 91% PPA (118/130). SVR12 ITT were 80% (8/10) for SOF+peg-interferon+ ribavirin, 86% (24/28) for SOF+ ribavirin, 95% (20/21) for SOF+simeprevir, 90% (64/71) for SOF/ledipasvir, 100% (8/8) for SOF+daclatasvir and 100% (5/5) for SOF/velpatasvir. The most common AEs were grade 1 (50; 35%), predominantly anemia (22%). DDIs or grade 4 AEs did not occur. Two pts died during the study period, both from reasons unrelated to SOFBT. In 3 pts with HCV-associated NHL, SOFBT was used alone without chemotherapy. Two of them had splenic marginal zone NHL and achieved complete remission (CR); the remaining pt had follicular lymphoma with stable cancer (SC) after SOFBT. No cases of de novo HCC occurred within 6 months of SOFBT. In the same period, 10% (4/40) of pts with SC had progression (acute leukemia, breast cancer, HCC and NHL in 1 each) and 5% (4/75) of pts with CR developed relapse (acute leukemia in 3, NHL in 1). More pts who failed SOFBT had cirrhosis (77% vs 27%, P = .001) and poorer adherence (≥ 2 missed appointments) (43% vs 4%, P = .001) than those with SVR. Conclusions: SOFBT is effective and safe in cancer pts; it improves access to CCT and may induce CR in selected NHL pts." @default.
• W2890908880 created "2018-09-27" @default.
• W2890908880 creator A5011158737 @default.
• W2890908880 creator A5016365495 @default.
• W2890908880 creator A5017742999 @default.
• W2890908880 creator A5021444537 @default.
• W2890908880 creator A5032750886 @default.
• W2890908880 creator A5033841614 @default.
• W2890908880 creator A5046065062 @default.
• W2890908880 creator A5055182697 @default.
• W2890908880 creator A5059324933 @default.
• W2890908880 creator A5089608031 @default.
• W2890908880 date "2017-05-20" @default.
• W2890908880 modified "2023-09-23" @default.
• W2890908880 title "Sofosbuvir-based therapy in patients with chronic hepatitis C virus infection and malignancies: A prospective study of 143 patients." @default.
• W2890908880 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.e18152" @default.
• W2890908880 hasPublicationYear "2017" @default.
• W2890908880 type Work @default.
• W2890908880 sameAs 2890908880 @default.
• W2890908880 citedByCount "3" @default.
• W2890908880 countsByYear W28909088802017 @default.
• W2890908880 countsByYear W28909088802019 @default.
• W2890908880 crossrefType "journal-article" @default.
• W2890908880 hasAuthorship W2890908880A5011158737 @default.
• W2890908880 hasAuthorship W2890908880A5016365495 @default.
• W2890908880 hasAuthorship W2890908880A5017742999 @default.
• W2890908880 hasAuthorship W2890908880A5021444537 @default.
• W2890908880 hasAuthorship W2890908880A5032750886 @default.
• W2890908880 hasAuthorship W2890908880A5033841614 @default.
• W2890908880 hasAuthorship W2890908880A5046065062 @default.
• W2890908880 hasAuthorship W2890908880A5055182697 @default.
• W2890908880 hasAuthorship W2890908880A5059324933 @default.
• W2890908880 hasAuthorship W2890908880A5089608031 @default.
• W2890908880 hasConcept C126322002 @default.
• W2890908880 hasConcept C159047783 @default.
• W2890908880 hasConcept C197934379 @default.
• W2890908880 hasConcept C2522874641 @default.
• W2890908880 hasConcept C2775999097 @default.
• W2890908880 hasConcept C2776408679 @default.
• W2890908880 hasConcept C2776455275 @default.
• W2890908880 hasConcept C2776461080 @default.
• W2890908880 hasConcept C2776979040 @default.
• W2890908880 hasConcept C2778019345 @default.
• W2890908880 hasConcept C2778390639 @default.
• W2890908880 hasConcept C2778986448 @default.
• W2890908880 hasConcept C2780040827 @default.
• W2890908880 hasConcept C71924100 @default.
• W2890908880 hasConcept C90924648 @default.
• W2890908880 hasConceptScore W2890908880C126322002 @default.
• W2890908880 hasConceptScore W2890908880C159047783 @default.
• W2890908880 hasConceptScore W2890908880C197934379 @default.
• W2890908880 hasConceptScore W2890908880C2522874641 @default.
• W2890908880 hasConceptScore W2890908880C2775999097 @default.
• W2890908880 hasConceptScore W2890908880C2776408679 @default.
• W2890908880 hasConceptScore W2890908880C2776455275 @default.
• W2890908880 hasConceptScore W2890908880C2776461080 @default.
• W2890908880 hasConceptScore W2890908880C2776979040 @default.
• W2890908880 hasConceptScore W2890908880C2778019345 @default.
• W2890908880 hasConceptScore W2890908880C2778390639 @default.
• W2890908880 hasConceptScore W2890908880C2778986448 @default.
• W2890908880 hasConceptScore W2890908880C2780040827 @default.
• W2890908880 hasConceptScore W2890908880C71924100 @default.
• W2890908880 hasConceptScore W2890908880C90924648 @default.
• W2890908880 hasIssue "15_suppl" @default.
• W2890908880 hasLocation W28909088801 @default.
• W2890908880 hasOpenAccess W2890908880 @default.
• W2890908880 hasPrimaryLocation W28909088801 @default.
• W2890908880 hasRelatedWork W1228449733 @default.
• W2890908880 hasRelatedWork W2114705120 @default.
• W2890908880 hasRelatedWork W2176407467 @default.
• W2890908880 hasRelatedWork W2323574296 @default.
• W2890908880 hasRelatedWork W2342705987 @default.
• W2890908880 hasRelatedWork W2468597926 @default.
• W2890908880 hasRelatedWork W2793850859 @default.
• W2890908880 hasRelatedWork W2980025725 @default.
• W2890908880 hasRelatedWork W2990928766 @default.
• W2890908880 hasRelatedWork W3140296766 @default.
• W2890908880 hasVolume "35" @default.
• W2890908880 isParatext "false" @default.
• W2890908880 isRetracted "false" @default.
• W2890908880 magId "2890908880" @default.
• W2890908880 workType "article" @default.